Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...
Low total cholesterol levels were tied to an increased risk of death for pulmonary fibrosis patients with disease of unknown cause in a study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback